# Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

> **NCT05980416** · PHASE1 · TERMINATED · sponsor: **Elevation Oncology** · enrollment: 88 (actual)

## Conditions studied

- Stomach Neoplasm
- Gastrointestinal Neoplasms
- Digestive System Neoplasm
- Neoplasms by Site
- Neoplasms

## Interventions

- **DRUG:** EO-3021
- **DRUG:** Ramucirumab (CYRAMZA®)
- **DRUG:** Dostarlimab

## Key facts

- **NCT ID:** NCT05980416
- **Lead sponsor:** Elevation Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-10
- **Primary completion:** 2025-05-07
- **Final completion:** 2025-06-02
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2025-11-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05980416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05980416, "Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05980416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*